News

Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favourable characteristics

26 May 2023

Phase 3 Study Finds Dupilumab Reduces COPD Exacerbations in Patients With Type 2 Inflammation

26 May 2023

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

26 May 2023

Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)

12 May 2023

Anti-HIV injection to be made in South Africa

12 May 2023

Valitor Presents Preclinical Data on its Long-acting Anti-VEGF Biologic in Development for Durable Treatment of Wet AMD at the Association for Research in Visio

28 April 2023

FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI)

28 April 2023

Skin patches may be more convenient MS antibody medicine

21 April 2023

Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use

21 April 2023

Long-acting GIPRA inhibits feeding and lowers body weight in mice with diet-induced obesity

24 March 2023

News

Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favourable characteristics

26 May 2023

Phase 3 Study Finds Dupilumab Reduces COPD Exacerbations in Patients With Type 2 Inflammation

26 May 2023

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

26 May 2023

Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)

12 May 2023

Anti-HIV injection to be made in South Africa

12 May 2023

Valitor Presents Preclinical Data on its Long-acting Anti-VEGF Biologic in Development for Durable Treatment of Wet AMD at the Association for Research in Visio

28 April 2023

FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI)

28 April 2023

Older Stories

Why choose Liverpool?
It’s an important question. And there are thousands of answers.

Study with Liverpool

Find a course

Search courses

Select type

Our courses

Research with real world impact

Our research

Research

Postgraduate Research

Research and business collaboration

Advancing knowledge to transform lives

About us

Our story

Key information

Our locations

Search

Find a course

Select type

News

Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favourable characteristics

Phase 3 Study Finds Dupilumab Reduces COPD Exacerbations in Patients With Type 2 Inflammation

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)

Anti-HIV injection to be made in South Africa

Valitor Presents Preclinical Data on its Long-acting Anti-VEGF Biologic in Development for Durable Treatment of Wet AMD at the Association for Research in Visio

FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI)

Skin patches may be more convenient MS antibody medicine

Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use

Long-acting GIPRA inhibits feeding and lowers body weight in mice with diet-induced obesity

News

Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favourable characteristics

Phase 3 Study Finds Dupilumab Reduces COPD Exacerbations in Patients With Type 2 Inflammation

FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder

Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)

Anti-HIV injection to be made in South Africa

Valitor Presents Preclinical Data on its Long-acting Anti-VEGF Biologic in Development for Durable Treatment of Wet AMD at the Association for Research in Visio

FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI)